{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:39:11Z","timestamp":1777088351935,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"DOI":"10.1007\/s40121-022-00645-5","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T10:15:57Z","timestamp":1652523357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens"],"prefix":"10.1007","author":[{"given":"Taylor","family":"Morrisette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Alosaimy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdalhamid M.","family":"Lagnf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy J.","family":"Frens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Veve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannette","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan W.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-043X","authenticated-orcid":false,"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,14]]},"reference":[{"key":"645_CR1","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2019. https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html. Accessed 23 Apr 2021."},{"key":"645_CR2","doi-asserted-by":"publisher","first-page":"ofx176","DOI":"10.1093\/ofid\/ofx176","volume":"4","author":"B Cai","year":"2017","unstructured":"Cai B, Echols R, Magee G, et al. Prevalence of carbapenem-resistant Gram-negative infections in the United States predominated by Acinteobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect Dis. 2017;4:ofx176.","journal-title":"Open Forum Infect Dis"},{"key":"645_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","volume":"75","author":"D van Duin","year":"2013","unstructured":"van Duin D, Kaye KS, Neuner EA, et al. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75:115\u201320.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"645_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fmicb.2019.00080","volume":"10","author":"C-C Sheu","year":"2019","unstructured":"Sheu C-C, Chang Y-T, Lin S-Y, et al. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:80.","journal-title":"Front Microbiol"},{"key":"645_CR5","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s40265-014-0267-8","volume":"74","author":"JA Viehman","year":"2014","unstructured":"Viehman JA, Nguyen M-H, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014;74:1315\u201333.","journal-title":"Drugs"},{"key":"645_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001825","volume":"12","author":"LH Kwong","year":"2015","unstructured":"Kwong LH, Agweyu A, English M, et al. An unsupported preference for intravenous antibiotics. PLoS Med. 2015;12: e1001825.","journal-title":"PLoS Med"},{"key":"645_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.18773\/austprescr.2020.008","volume":"43","author":"K McCarthy","year":"2020","unstructured":"McCarthy K, Avent M. Oral or intravenous antibiotics? Aust Prescr. 2020;43:45\u20138.","journal-title":"Aust Prescr"},{"key":"645_CR8","first-page":"425","volume":"31","author":"L Ho-Kwong","year":"2019","unstructured":"Ho-Kwong L, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;31:425\u201336.","journal-title":"N Engl J Med"},{"key":"645_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","volume":"31","author":"K Iversen","year":"2019","unstructured":"Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;31:415\u201324.","journal-title":"N Engl J Med"},{"key":"645_CR10","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1128\/AAC.01066-13","volume":"58","author":"MP Draper","year":"2014","unstructured":"Draper MP, Weir S, Macone A, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother. 2014;58:1279\u201383.","journal-title":"Antimicrob Agents Chemother"},{"key":"645_CR11","doi-asserted-by":"publisher","unstructured":"Iregui A, Landman D, Quale J. Activity of omadacycline and other tetracyclines against contemporary Gram-negative pathogens from New York City hospitals. Microb Drug Resist. 2021;27:190-5. https:\/\/doi.org\/10.1089\/mdr.2019.0423.","DOI":"10.1089\/mdr.2019.0423"},{"key":"645_CR12","first-page":"e02327","volume":"62","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Huband MD, Hortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2018;62:e02327-e2417.","journal-title":"Antimicrob Agents Chemother"},{"key":"645_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"A-P Magiorakos","year":"2012","unstructured":"Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant, and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"645_CR14","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 31st ed. CLSI supplement. M100. Wayne: Clinical and Laboratory Standards Institute; 2021."},{"key":"645_CR15","unstructured":"US Food and Drug Administration (FDA). Antibacterial susceptibility test interpretive criteria. 2021. https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria. Accessed 22 Apr 2021."},{"key":"645_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.7150\/jbji.42448","volume":"5","author":"PR Oliveira","year":"2020","unstructured":"Oliveira PR, Carvalho VC, Saconi ES, et al. Tigecycline versus colistin in the treatment of carbapenem-resistant Acinetobacter baumannii complex osteomyelitis. J Bone Jt Infect. 2020;5:60\u20136.","journal-title":"J Bone Jt Infect"},{"key":"645_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijantimicag.2015.03.001","volume":"45","author":"A Potron","year":"2015","unstructured":"Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents. 2015;45:568\u201385.","journal-title":"Int J Antimicrob Agents"},{"key":"645_CR18","first-page":"e01784","volume":"61","author":"W Lin","year":"2016","unstructured":"Lin W, Flarakos J, Du Y, et al. Pharmacokinetics, distribution, metabolism, and excretion of Omadacycline following a single intravenous of oral dose of 14C-omadacycline in rats. Antimicrob Agents Chemother. 2016;61:e01784-e1816.","journal-title":"Antimicrob Agents Chemother"},{"key":"645_CR19","first-page":"e02368","volume":"61","author":"AJ Lepak","year":"2017","unstructured":"Lepak AJ, Zhao M, Marchillo K, et al. In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model. Antimicrob Agents Chemother. 2017;61:e02368-e2416.","journal-title":"Antimicrob Agents Chemother"},{"key":"645_CR20","first-page":"e00624","volume":"63","author":"AJ Lepak","year":"2019","unstructured":"Lepak AJ, Zhao M, Marchillo K, et al. In vivo pharmacodynamics of omadacycline against Staphylococcus aureus in the neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2019;63:e00624-e719.","journal-title":"Antimicrob Agents Chemother"},{"key":"645_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/9781420017137.013","volume-title":"Antimicrobial pharmacodynamics in theory and clinical practice","author":"D Andes","year":"2007","unstructured":"Andes D, Craig W. Pharmacokinetics and pharmacodynamics of tetracyclines. In: Nightingale CH, Ambrose PG, Drusano GL, Murakawa T, editors. Antimicrobial pharmacodynamics in theory and clinical practice. 2nd ed. New York: Informa Healthcare USA; 2007. p. 267\u201378.","edition":"2"},{"key":"645_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/jac\/dkaa508","volume":"76","author":"AR Noel","year":"2021","unstructured":"Noel AR, Attwood M, Bowker KE, et al. In vitro pharmacodynamics of Omadacycline against Escherichia coli and Acinetobacter baumannii. J Antimicrob Chemother. 2021;76:667\u201370. https:\/\/doi.org\/10.1093\/jac\/dkaa508.","journal-title":"J Antimicrob Chemother"},{"key":"645_CR23","doi-asserted-by":"publisher","first-page":"e01487","DOI":"10.1128\/AAC.01487-17","volume":"62","author":"LA Bundrant","year":"2018","unstructured":"Bundrant LA, Tzanis E, Garrity-Ryan L, et al. Safety and pharmacokinetics of the aminomethylcycline antibiotic Omadacycline administered to healthy subjects in oral multiple-dose regimens. Antimicrob Agents Chemother. 2018;62:e01487-e1517.","journal-title":"Antimicrob Agents Chemother"},{"key":"645_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517\u201327.","journal-title":"N Engl J Med"},{"key":"645_CR25","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","volume":"19","author":"W O\u2019Riordan","year":"2019","unstructured":"O\u2019Riordan W, Cardenas C, Shin E, et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19:1080\u201390.","journal-title":"Lancet Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00645-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-022-00645-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00645-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T10:27:53Z","timestamp":1652524073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-022-00645-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,14]]},"references-count":25,"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s40121-022-00645-5","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,14]]},"assertion":[{"value":"24 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}